NXTC - NextCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.53
-0.51 (-1.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close40.04
Open40.03
Bid0.00 x 800
Ask0.00 x 800
Day's Range38.77 - 41.73
52 Week Range13.86 - 44.69
Volume123,713
Avg. Volume71,889
Market Cap897.916M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.92
Earnings DateAug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.67
Trade prices are not sourced from all markets
  • GlobeNewswire

    NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on September 10, 2019 at 10:00 am ET. A live audio webcast will be available through the Events and Presentations page of the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Reports Second Quarter 2019 Financial Results

    BELTSVILLE, Md., Aug. 12, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?

    The big shareholder groups in NextCure, Inc. (NASDAQ:NXTC) have power over the company. Large companies usually have...

  • 2 Small-Cap Biotech IPOs You Should Know About
    Motley Fool

    2 Small-Cap Biotech IPOs You Should Know About

    The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.

  • GlobeNewswire

    NextCure Reports First Quarter 2019 Financial Results

    BELTSVILLE, Md., June 10, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Pricing of Initial Public Offering of Common Stock

    BELTSVILLE, Md., May 08, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Benzinga

    IPO Outlook For The Week: Uber (And 11 Others)

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...